PubMed · 1500704
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R King, J Y Lau, R Williams. 1992. Problems in treating chronic HDV infection.. https://doi.org/10.1016/0168-8278(92)90195-u
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Hepatitis D virus (HDV) is a subviral satellite with hepatitis B virus (HBV) as its natural helper virus. After entry into hepatocytes, it utilizes host cellular enzymes to replicate by a double-rolling-circle mechanism. HDV is most often transmitted by contact with contaminated blood and body fluid, similar to HBV infection. Approximately 5% of the global HBV carriers are coinfected with HDV, leading to a total of 10-15 million HDV carriers worldwide. HDV infection can occur concurrently with HBV infection (coinfection) or in a patient with established HBV infection (superinfection). The pathogenesis of HDV remains controversial. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide. At present, therapy for chronic HDV infection is by the use of interferon-alpha. Compared to chronic hepatitis B or C, CHD treatment requires a higher dosage and a longer duration of treatment, and post-treatment relapses are common. In order to prevent the progression of CHD and its related morbidity and mortality, more effective treatments are needed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.